靶向组织黏附低密度脂蛋白隐蔽表位的单克隆自身抗体用于动脉粥样硬化分子成像
该研究从Ldlr-/-小鼠制备单克隆自身抗体LO9,其识别与基质结合的原生LDL上apoB氨基端20氨基酸表位(P5),而不识别液相LDL。LO9在鼠和人类稳定及破裂冠状动脉粥样硬化中反应,静脉注射后在小鼠主动脉弓内皮下定位于巨噬细胞附近,提示其可作为动脉粥样硬化分子成像与治疗递送的靶向载体。
要点
- LO9识别基质黏附原生LDL的隐蔽表位,不结合液相LDL。
- LO9在人和小鼠粥样硬化斑块中均可见,包括稳定和破裂斑块。
- 静脉注射LO9可靶向主动脉弓内皮下的巨噬细胞附近。
核心结论
- LO9是首个针对组织基质黏附所暴露的原生LDL表位的IgG自身抗体,具有动脉粥样硬化分子成像和治疗递送潜力。
研究设计与样本
- 研究从Ldlr-/-小鼠制备杂交瘤,筛选出IgG2b同型自身抗体LO9进行表征。
- 在体外评估LO9与原生LDL、氧化LDL的结合特性,并定位表位至apoB氨基端20氨基酸肽段P5。
- 在鼠和人类粥样硬化组织验证LO9的反应性,并行体内近红外荧光分子断层成像和离体共聚焦显微镜观察。
关键影像表现/征象
- LO9与结合于固相基质的原生LDL反应良好,与氧化LDL反应较弱。
- 液相原生LDL不能中和LO9与固相原生LDL的结合,提示表位暴露依赖黏附。
- LO9定位于apoB球状氨基端的20氨基酸序列P5。
- LO9在鼠粥样硬化及人稳定和破裂冠状动脉粥样硬化中与抗原反应。
- 静脉注射LO9后,近红外荧光分子断层成像和共聚焦显微镜显示其定位于Ldlr-/-小鼠主动脉弓内皮下方、巨噬细胞附近。
临床应用与阅片要点
- LO9可作为靶向黏附原生LDL的分子探针候选,用于动脉粥样硬化斑块成像。
- 识别隐蔽表位的特点提示在报告分子成像时需注意区分循环LDL与组织黏附LDL的信号。
局限性
- 研究主要在小鼠模型和离体人组织中进行,体内人体验证尚未开展。
- 样本量有限,且未报告诊断效能指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Antibody-based constructs for molecular imaging and therapeutic delivery provide promising opportunities for the diagnosis and treatment of atherosclerosis.
OBJECTIVES: The authors aimed to generate and characterize immunoglobulin (Ig)G monoclonal autoantibodies in atherosclerosis for targeting of novel molecular determinants.
METHODS: The authors created hybridomas from an unimmunized low-density lipoprotein (LDL) receptor-deficient (Ldlr-/-) mouse and selected an IgG2b isotype autoantibody, LO9, for further characterization.
RESULTS: LO9 reacted well with native LDL bound to immobilized matrix components and less well to oxidized LDL. LO9 binding to immobilized native LDL was not neutralized by fluid-phase native LDL, indicating an adhesion-dependent epitope. The authors localized the epitope to a 20 amino-acid peptide sequence (P5) in the globular amino-terminus of apolipoprotein B. LO9 reacted with antigen in mouse atherosclerosis and in both human stable and ruptured coronary atherosclerosis. Furthermore, in vivo near-infrared fluorescence molecular tomographic imaging, and ex vivo confocal microscopy showed that intravenously injected LO9 localized beneath endothelium of the aortic arch in Ldlr-/- mice, in the vicinity of macrophages.
CONCLUSIONS: The authors believe LO9 is the first example of an IgG autoantibody that reacts with a native LDL epitope revealed by adherence to tissue matrix. Antibodies against adherent native LDL have potential as molecular targeting agents for imaging of and therapeutic delivery to atherosclerosis.
引用
- Khamis, Hartley, Caga-Anan, et al. Monoclonal Autoantibody Against a Cryptic Epitope on Tissue-Adherent Low-Density Lipoprotein for Molecular Imaging in Atherosclerosis. JACC Cardiovasc Imaging. 2022. PMID: 35926905. doi:10.1016/j.jcmg.2022.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。